Effects of cilostazol on LPS-stimulated adhesion and soluble adherent molecules release

罗景慧,林永成,陈志良,尾関真理子,林秀晴,渡边裕司

DOI: https://doi.org/10.3321/j.issn:1001-1978.2003.12.016

2003-01-01

Abstract:AIM: To examine the effect of cilostazol, a novel selective phosphodiesterase type 3 inhibitor, on adherence between neutrophils and human umbilical endothelial cells (HUVECs) and investigate its possible mechanisms. METHODS: Confluent HUVECs between 4-6 passages were used and stimulated by lipopolysaccharide (LPS, 5 mg · L-1) with or without coincubation of cilostazol (1-10 μmol · L-1) for 24 h. Soluble cell adhesion molecules (sCAMs), including vascular cell adhesion molecule-1 (sVCAM-1), intercellular adhesion molecule-1 (sICAM-1) and endothelial leukocyte adhesion molecule-1 (sELAM-1, sE-selectin) in cell culture medium were measured by ELISA. RESULTS: Cilostazol (1-10 μmol · L-1) inhibited adherence between neutrophils and HUVECs in a dose-dependent manor. At the same time, cilostazol didn't affect sICAM-1 and sE-selectin release from LPS-stimulated HUVECs, but in contrast, it significantly inhibited sVCAM-1 production under the same experiment condition, and this effect was canceled by H-89, an inhibitor of protein kinase A (PKA). CONCLUSION: Cilostazol significantly inhibits adherence between neutrophils and HUVECs, and downregulates sVCAM-1 release from LPS-activated HUVECs, and these effects on cytokine-challenged endothelial cells might be via a PKA-dependent pathway. The present result suggests that cilostazol partially eliminates some of the adherent reactions of HUVECs to LPS, a deleterious cytokine, and it is reasonable to consider that cilostazol might be a strategy for preventing atherosclerosis and other cardiovascular diseases.